Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Treatment outcomes from primary CTCL

Amra Osmancevic • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases

Amra Osmancevic, MD, PhD, University of Gothenburg, Gothenburg, Sweden, discuses the findings of a retrospective study investigating the diagnostics and treatment outcomes of patients with primary T-cell lymphoma (CTCL), reporting that most patients were treated with targeted therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Amra Osmancevic

0:32
Patient selection for CTCL
Amra Osmancevic • 15 Oct 2021
1:22
Diagnostics and treatment outcomes from primary CBCL
Amra Osmancevic • 15 Oct 2021
0:43
Classifying CBCL subtypes
Amra Osmancevic • 15 Oct 2021
1:05
The diagnostic work-up of CBCL in Sweden
Amra Osmancevic • 15 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals